High-intensity interval Nordic walking for Coronary Artery Disease

Phase-Based Progress Estimates
University of Ottawa Heart Institute, Ottawa, Canada
Coronary Artery Disease+2 More
High-intensity interval Nordic walking - Behavioral
All Sexes
What conditions do you have?

Study Summary

Coronary revascularization, such as heart bypass surgery (CABG) and percutaneous coronary intervention (PCI [inserting a stent to open up blood vessels]) improve survival for people with coronary artery disease. Yet, many patients suffer from poor physical and mental health after coronary revascularization. Traditional cardiac rehabilitation involving moderate-to-vigorous intensity continuous training (MICT) improves physical and mental health. However, alternative exercise programs, such as high-intensity interval training (HIIT) and Nordic walking may provide superior benefits. Nordic walking is like Nordic skiing but uses specifically designed poles for walking. Nordic walking involved core, upper and lower body muscles, resulting in greater energy expenditure while reducing loading stress at the knee. To date, HIIT used in cardiac rehabilitation settings has focused on lower body (e.g., leg cycling). The investigators are not aware of HIIT protocols that target both upper and lower body at the same time. An exercise program that combines HIIT and Nordic walking (HIIT-NoW) may offer an alternative time-efficient whole-body exercise to improve physical and mental health. This study will test if HIIT-NoW can be an alternative exercise option to improve physical and mental health in patients with coronary artery disease.

Eligible Conditions

  • Coronary Artery Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

7 Primary · 12 Secondary · Reporting Duration: Baseline to week 11 follow up

Week 11
Adverse events
Blood pressure
Cardiorespiratory fitness
Fat mass
Fat-free mass
Functional capacity
Heart Disease specific Quality of life (HeartQoL)
Physical activity levels
Quality of life (QoL)
Subjective exercise experiences
Subjective functinal capacity
Waist circumference

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

1 of 2
High-intensity interval Nordic walking
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: High-intensity interval Nordic walking · No Placebo Group · N/A

High-intensity interval Nordic walking
Experimental Group · 1 Intervention: High-intensity interval Nordic walking · Intervention Types: Behavioral
ActiveComparator Group · 1 Intervention: Standard cardiovascular rehabilitation · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 11 follow up
Closest Location: University of Ottawa Heart Institute · Ottawa, Canada
Photo of Ottawa 1Photo of Ottawa 2Photo of Ottawa 3
2011First Recorded Clinical Trial
52 TrialsResearching Coronary Artery Disease
145 CompletedClinical Trials

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
176 Previous Clinical Trials
87,948 Total Patients Enrolled
47 Trials studying Coronary Artery Disease
37,970 Patients Enrolled for Coronary Artery Disease
Jennifer L Reed, PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation
6 Previous Clinical Trials
609 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
135 Patients Enrolled for Coronary Artery Disease

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have coronary artery disease.
You are willing to come onsite for exercise sessions.
You are able to perform a cardiopulmonary exercise testing (CPET).
You are at least 40 years of age.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.